Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

A New Immunotherapy Could Make a Difference in Cancer Treatment: Anti-LAG-3 Relatlimab

A New Immunotherapy Could Make a Difference in Cancer Treatment: Anti-LAG-3 Relatlimab

On 6 January 2022, The New England Journal of Medicine reported the phase II/III RELATIVITY-047 clinical trial, in which Dr. Hussein Tawbi and colleagues showed that adding the lymphocyte activation gene 3 (LAG-3) blocker relatlimab to another approved immunotherapy, the PD-1 inhibitor nivolumab, in previously untreated patients with metastatic or surgically unresectable melanoma significantly prolonged progression-free survival.

Summary Result of the RELATIVITY-047 Trial

  • Relatlimab plus nivolumab significantly improved progression-free survival compared with nivolumab alone.
  • Median progression-free survival (PFS) was 10.1 versus 4.6 months, and the 1-year PFS rates were 48% versus 36%, respectively.

Relatlimab plus nivolumab in advanced melanoma: PFS data from the RELATIVITY 047 trial, NEJM 2022

Rationale for the Study

LAG-3 and PD-1 are two different immune checkpoints that inactivate the immune system’s T cells. The combination of relatlimab, an LAG-3-blocking antibody, and nivolumab, a PD-1-blocking antibody, had previously shown safety and antitumor activity in patients with previously treated melanoma, but this study was conducted to investigate its efficacy in previously untreated melanoma.

Below, the mechanisms of action of relatlimab and nivolumab are illustrated simply:

How does anti-LAG 3 relatlimab work?

Study Details

In this double-blind clinical trial, 714 patients from sites in North America, Central America, South America, Europe, Australia and New Zealand were randomly assigned between May 2018 and December 2020 to receive relatlimab/nivolumab (355 patients) or nivolumab alone (359 patients).

Treatment consisted of a combination of 160 mg relatlimab and 480 mg nivolumab, or 480 nivolumab alone, every 4 weeks until disease progression or unacceptable side effects.

The stratification factors were

  • LAG-3 expression status (≥ 1% or < 1% of positively staining immune cells) and
  • PD-L1 expression status (≥ 1% or < 1% of tumor cells).

The primary endpoint measured in the study was progression-free survival, assessed by blinded independent central review.

Results

  • At the analysis as of March 2021, the median follow-up was 13.2 months.
  • Median progression-free survival was 10.1 months in the relatlimab/nivolumab group (95% confidence interval [CI] = 6.4–15.7 months) and 4.6 months in the nivolumab group (95% CI = 3.4–5.6 months) (hazard ratio [HR] = 0.75, 95% CI = 0.62–0.92, P = 0.006).
  • At month 12, PFS rates were 47.7% (95% CI = 41.8%-53.2%) and 36.0% (95% CI = 30.5%-41.6%).
  • Combination treatment showed better progression-free survival regardless of tumor burden, LDH level and other prognostic factors.
The relatlimab combination provides better progression-free survival regardless of tumor burden, LDH level and prognostic factors

Side Effects

Serious (grade 3 or 4) side effects occurred in 40.3% of patients in the relatlimab/nivolumab group and 33.4% of the nivolumab group, and were considered treatment-related in 18.9% versus 9.7%.

The most common treatment-related side effects of any grade in the relatlimab/nivolumab group were itching (23.4% versus 15.9%), fatigue (23.1% versus 12.8%) and rash (15.5% versus 12.0%); the most common grade 3 or 4 side effect was fatigue (1.1% versus 0.3%).

Infusion-related reactions occurred in 5.9% versus 3.6% of patients.

The most common immune-mediated side effects of any grade in the relatlimab/nivolumab group were hypothyroidism or thyroiditis (18.0% versus 13.9%), rash (9.3% versus 6.7%), and diarrhea/colitis (6.8% versus 3.1%); the most common grade 3 or 4 events were hepatitis (3.9% versus 1.1%) and adrenal insufficiency (1.4% versus 0%).

Conclusion

Until now, the only immune checkpoints for which effective drugs had been developed were CTLA-4, PD-1 and PD-L1. With LAG-3, another new targetable checkpoint has been identified in oncology practice.

For the treatment of melanoma patients in this situation, the ipilimumab plus nivolumab combination in January 2016 had previously received accelerated FDA approval for both BRAF V600 wild-type and mutant patients, based on the PFS results of CheckMate-067. In that study, median PFS was 11.5 months in the combination arm versus 6.9 months with nivolumab alone.

In the study discussed here, combined inhibition of LAG-3 and PD-1 provided a greater progression-free survival benefit than inhibition of PD-1 alone in previously untreated patients with metastatic or surgically unresectable melanoma. The combination of relatlimab and nivolumab showed no new side-effect signals. In the future, we may hear that this combination is also effective in other cancers and has received FDA approvals.

Sources

Hussein A. Tawbi, M.D., Ph.D., et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med 2022; 386:24-34

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

A New Immunotherapy Could Make a Difference in Cancer Treatment: Anti-LAG-3 Relatlimab

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy